Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

MOL4239 · WP-1220

Other · developed by Moleculin, LLC

Phase 2 Most advanced trial (none active)
MBRX Developer
2 Registered trials

What is MOL4239?

MOL4239 is an investigational drug studied in Psoriasis, Cutaneous T-Cell Lymphoma/Mycosis Fungoides.

At a glance

Also known as
WP-1220
Drug type
Other
Therapy area
Dermatology
Developer
Moleculin, LLC (MBRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
PTN9LJL6PY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01826201 Phase 2 Psoriasis Completed MBRX
NCT04702503 Phase 1 Cutaneous T-Cell Lymphoma/Mycosis Fungoides Completed MBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cutaneous T-Cell Lymphoma/Mycosis FungoidesPsoriasis

More from Moleculin, LLC

Liposomal Annamycin Phase 1/2 WP1122 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MBRX page.

Follow MBRX, the company behind MOL4239

See MBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MBRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.